[lemma=menstrual] [lemma=blood] [□]
[lemma=menstrual] [lemma=blood] [□=□]
[lemma=menstrual] [lemma=blood] [□ & □]
Progestogen therapy during the luteal phase was significantly less effective at reducing menstrual blood loss when compared with tranexamic acid , danazol and the progesterone releasing intrauterine system ( IUS ) . These include less painful menstruation , less menstrual blood loss and anemia , fewer pelvic infections , and fewer cancers of the ovary and the lining of the uterus . The inclusion criteria were randomised comparisons of oral progestogen therapy versus placebo or other medical treatments in women of reproductive years with regular heavy periods measured either objectively or subjectively and with no pathological or iatrogenic causes for their heavy menstrual blood loss . Progestogen therapy for 21 days of the cycle results in a significant reduction in menstrual blood loss , although women find the treatment less acceptable than intrauterine levonorgestrel . The main outcomes were menstrual blood loss , the number of women experiencing adverse effects , weight gain , withdrawals due to adverse effects and dysmenorrhoea .